Cargando…

Correction: Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542525/ https://www.ncbi.nlm.nih.gov/pubmed/31145763 http://dx.doi.org/10.1371/journal.pone.0217670

Ejemplares similares

Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs
por: Clemens, Daniel L., et al.
Publicado: (2019)

AI-Enabled Parabolic Response Surface Approach Identifies Ultra Short-Course Near-Universal TB Drug Regimens
por: Horwitz, Marcus A., et al.
Publicado: (2019)

Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility
por: Lee, Bai-Yu, et al.
Publicado: (2018)

Predicting drug approvals: The Novartis data science and artificial intelligence challenge
por: Siah, Kien Wei, et al.
Publicado: (2021)

The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB
por: Muniyandi, Malaisamy, et al.
Publicado: (2023)

An open-source drug discovery platform enables ultra-large virtual screens
por: Gorgulla, Christoph, et al.
Publicado: (2020)

UNITE4TB: a new consortium for clinical drug and regimen development for TB
por: Boeree, M. J., et al.
Publicado: (2021)

An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology
por: Bachar, Neta, et al.
Publicado: (2021)

Studies with Parabolic Parabolic Linear Parabolic (PPLP) momentum function in the LHC
por: Solfaroli Camillocci, Matteo, et al.
Publicado: (2018)

Artificial intelligence enabled ChatGPT and large language models in drug target discovery, drug discovery, and development
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance
por: Ryu, Alexander J., et al.
Publicado: (2023)

Artificial Intelligence in Drug Design
por: Hessler, Gerhard, et al.
Publicado: (2018)

Artificial intelligence enhanced sensors - enabling technologies to next-generation healthcare and biomedical platform
por: Wang, Chan, et al.
Publicado: (2023)

Universal artificial intelligence platform for collaborative management of cataracts
por: Wu, Xiaohang, et al.
Publicado: (2019)

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
por: Rodriguez, Carly A., et al.
Publicado: (2023)

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
por: Patil, S. B., et al.
Publicado: (2023)

Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
por: Singh, Pravin K., et al.
Publicado: (2019)

Artificial intelligence in drug discovery and development
por: Paul, Debleena, et al.
Publicado: (2021)

Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial
por: Weng, Taoping, et al.
Publicado: (2021)

Nonlinear parabolic equations and hyperbolic-parabolic coupled systems
por: Zheng, Songmu
Publicado: (1995)

Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different
por: LaHood, Allison, et al.
Publicado: (2022)

Digital Research Environment(DRE)-enabled Artificial Intelligence (AI) to facilitate early stage drug development
por: Barrett, Jeffrey S., et al.
Publicado: (2023)

Artificial Intelligence and Machine Learning in the Diagnosis and Management of Stroke: A Narrative Review of United States Food and Drug Administration-Approved Technologies
por: Chandrabhatla, Anirudha S., et al.
Publicado: (2023)

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
por: Amen, Triana, et al.
Publicado: (2016)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

Is intermittent short-course anti-TB regimen as efficient and safe as daily anti-TB regimen for treating childhood TB?
por: Bhaumik, Soumyadeep
Publicado: (2015)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Artificial Intelligence and the Future of the Drug Safety Professional
por: Danysz, Karolina, et al.
Publicado: (2018)

Artificial intelligence in COVID-19 drug repurposing
por: Zhou, Yadi, et al.
Publicado: (2020)

Optimal dynamic regimens with artificial intelligence: The case of temozolomide
por: Houy, Nicolas, et al.
Publicado: (2018)

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Repurposing of approved cardiovascular drugs
por: Ishida, Junichi, et al.
Publicado: (2016)

Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
por: Chalkidou, Kalipso, et al.
Publicado: (2020)

Modeling drug mechanism of action with large scale gene-expression profiles using GPAR, an artificial intelligence platform
por: Gao, Shengqiao, et al.
Publicado: (2021)

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic
por: Tiberi, Simon, et al.
Publicado: (2021)

Honey: Single food stuff comprises many drugs
por: Khan, Shahid Ullah, et al.
Publicado: (2018)

Trends in the Approval and Quality Management of Artificial Intelligence Medical Devices in the Republic of Korea
por: Lim, Kyoungtaek, et al.
Publicado: (2022)

Diagnostic performance of artificial intelligence approved for adults for the interpretation of pediatric chest radiographs
por: Shin, Hyun Joo, et al.
Publicado: (2022)

Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future
por: Riccardi, Niccolò, et al.
Publicado: (2020)

Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment
por: Saurabh, Suman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0tggdbmqki1v8cnj4527vk3abj